Stockreport
Summit Therapeutics' (SMMT) CEO Glyn Edwards on Q4 2017 Results - Earnings Call Transcript [Seeking Alpha]
US:NASDAQ Investor Relations: summitplc.com/investors/investor-centre
PDF
Summit Therapeutics' (SMMT) CEO Glyn Edwards on Q4 2017 Results - Earnings Call Transcript
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | SMMT | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
SMMT alerts
SMMT alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SMMT alerts
High impacting SUMMIT THERAPEUTICS PLC AMERICA news events
Weekly update
A roundup of the hottest topics
SMMT
NEWS
NEWS
- Summit Therapeutics to Participate in Upcoming Investor Events[GlobeNewswire]
- Surrender of Share Options[GlobeNewswire]
- Summit Highlights Phase 3-Ready Precision Antibiotic Ridinilazole at IDWeek 2018[GlobeNewswire]
- SUMMIT THERAPEU/S (NASDAQ: SMMT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.50 price target on the stock.[MarketBeat]
- SUMMIT THERAPEU/S (NASDAQ: SMMT) was downgraded by analysts at ValuEngine from a "sell" rating to a "strong sell" rating.[MarketBeat]
- More
SMMT
SEC Filings
SEC Filings
- 10/9/18 - Form 6-K
- 9/20/18 - Form 6-K
- 9/5/18 - Form 6-K
- SMMT's page on the SEC website
- More